OUR FAMILY IS BUILT ON STRONG
VECTOR VACCINE PROTECTION

Click and drag your mouse around
the screen to explore the wall. Touch and drag
to explore the wall.

LOADING WALL

POULVAC® PROCERTA™ HVT-IBD IS FAST FLOCK PROTECTION.

SEE THE BENEFITS >

RAISE A WELL-PROTECTED FLOCK WITH POULVAC® PROCERTA™ HVT-ND.

SEE THE BENEFITS >

The right tools to optimize your health outcomes

Zoetis is committed to further exploring vector vaccines to bring new solutions and insights to the poultry industry.

Fast-acting Vaccines

The fast-acting line of Poulvac^® Procerta^™ vector vaccines are valuable tools to protect against costly viral challenges.

Effective Prevention

Poulvac^® vaccines work effectively to prevent infectious bursal disease virus, Marek’s disease, infectious bronchitis, Newcastle disease, Escherichia coli (E. coli) and Salmonella, among other challenges.

Insightful Diagnostics

Diagnostics services identify viral field strains and the timing and severity of disease challenges to help veterinarians make informed decisions.

Service That Sets Us Apart

Embrex^® biodevices

The line of Poulvac^® Procerta^™ vaccines pairs with the unmatched performance and support associated with the leading Inovoject^® system, an Embrex^® biodevice for vaccinating eggs in ovo.

About embrex^® >

Technical service veterinarians

Poulvac^® Procerta^™ vaccines are supported by technical service veterinarians of Zoetis who work with poultry producers and veterinarians to develop customized vaccination programs.

¹ Data on file, Study Report No. B815R-US-19-B80, Zoetis Inc.
² Data on file, Study Report No. B815W-US-19-A92, Zoetis Inc.
³ Data on file, Study Report No. B815R-US-19-B22, Zoetis Inc.
⁴ Data on file, Study Report No. B812W-US-18-919, Zoetis Inc.
⁵ Data on file, Study Report No. B814R-US-19-B15, Zoetis Inc.
⁶ Alkie TN, Rautenschlein S. Infectious bursal disease virus in poultry: current status and future prospects. Vet Med: Res Rep. 2016;7:9-18.
⁷ Cookson K, Featherson S, Barker A, Schaeffer J. A survey of wild type IBDV isolated from broiler flocks in the United States since 2014. Presented at: Southern Conference of Avian Diseases; 2020; Atlanta, GA.
⁸ Data on file, Study Report No. B818R-US-19-B94, Zoetis Inc.
⁹ Rennier Associates Inc. 2018 US Broiler-Health Market Tracker.
¹⁰ Data on file, Study Report No. B815R-US-19-B20, Zoetis Inc.
¹¹ Data on file, Study Report No. B812R-US-19-A69, Zoetis Inc.
¹² Data on file, Study Report No. B815W US 18 A46, Zoetis Inc.
¹³ Data on file, Study Report No. B815R‑US‑18‑985, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2021 Zoetis Services LLC. All rights reserved. BIO-00212R1

< back to family wall

Poulvac^® Procerta^™ HVT‑IBD

SPEED RUNS IN OUR FAMILY

New from Zoetis, Poulvac^® Procerta^™ HVT‑IBD is the latest member of the poultry lineage, bringing speed and endurance to prevent infectious bursal disease virus (IBDV).^1-5

Product Details

Raise a Better Broiler

STRONG PROTECTION, LESS VULNERABLE FLOCKS

IBDV remains one of the most challenging poultry health concerns, and it is evolving due to genetic variation.⁶ The AL‑2 variant has emerged as the most common IBDV challenge in U.S. broiler production, present in 52% of field samples recorded from 2014 to 2019.⁷

TIMING IS CRITICAL WITH IBDV

Poulvac^® Procerta^™ HVT‑IBD protects chicks fast and delivers strong overall protection to contemporary IBDV challenges — including AL‑2, and it demonstrated protection against IBDV in chicks with high maternal antibody levels.^1-5,8 This means flocks are less vulnerable for less time overall.

FAST PROTECTION AGAINST CRITICAL BROILER IBDV CHALLENGES AT DAY 14

Poulvac Procerta HVT-IBD demonstrated strong protection against various IBDV challenges common to the U.S. broiler industry.

In a study assessing bursal atrophy with no maternal antibodies present, Poulvac Procerta HVT-IBD provided 78% protection against a Day 14 AL-2 IBDV challenge^.1
In separate in ovo vaccination studies where birds had no maternal antibodies, Poulvac Procerta HVT-IBD provided 96% classic IBDV protection at Day 14, based on acute bursal lesions.^2,3
In a study assessing bursal atrophy, Poulvac Procerta HVT-IBD provided 95% protection following a Day 14 classic IBDV challenge.⁴

Download Studies

“Because IBDV infection is subject to genetic variation, it’s important to determine what IBD types you have and build a customized vaccination program for specific challenges.”

Kalen Cookson
DVM, MAM, Dipl. ACPV
Director of Clinical Research, Zoetis

Long-lasting Layer Protection

STRONG IMMUNITY, LESS VULNERABILITY

IBDV remains one of the most challenging poultry health concerns, and it is evolving due to genetic variation.⁶

Flock health managers rely heavily on recombinant vector vaccines with a herpesvirus of turkeys (HVT) backbone as valuable tools for protecting against both Marek’s disease and IBDV, among other viral challenges. About 60% of the U.S. layer population was vaccinated with a vector HVT‑IBD vaccine as of 2019.⁹

EVERY DAY COUNTS WHEN IT COMES TO IBDV

Timing is everything in egg production, from the day pullet chicks hatch throughout the hen’s entire production cycle. Poulvac^® Procerta^™ HVT‑IBD protects chicks fast and delivers strong overall protection to common IBDV challenges, providing fast, long‑lasting protection.^4,10-11

FAST PROTECTION AGAINST CRITICAL LAYER IBDV CHALLENGES AT DAY 14

Poulvac Procerta HVT-IBD has demonstrated strong protection against various IBDV challenges common to the U.S. layer industry.

In a study with no maternal antibodies present, Poulvac Procerta HVT-IBD provided 98% protection against a Day 14 classic IBDV challenge, based on acute bursal lesions.¹⁰
In a study assessing bursal atrophy in pullets, Poulvac Procerta HVT-IBD provided 100% protection following a Day 14 classic IBDV challenge.⁴
Poulvac Procerta HVT-IBD also demonstrated 90% efficacy at Day 14 against a very virulent IBDV challenge (California isolate) using subcutaneous injection.¹¹

Download Studies

“IBDV remains a leading challenge to the commercial egg industry.”

John Brown
DVM
Senior Technical Services Veterinarian, Zoetis

< back to family wall

Poulvac^® Procerta^™ HVT‑ND

YOU WORK HARD TO PROTECT YOUR FLOCK. SO DO WE.

The latest HVT‑ND vector designed to protect your flock against Marek’s disease and Newcastle disease.

Product Details

Fast-acting Onset of Immunity

Poulvac^® Procerta^™ HVT‑ND delivers protection against Marek’s disease combined with fast onset of immunity against Newcastle disease, showing 93% protection at 19 days of age.¹²

Download Study

When Immune Response Is High, Confidence Is Too

“Poulvac Procerta HVT‑ND was developed using our new vector platform that was built using advanced scientific techniques.”

Kalen Cookson
DVM, MAM, Dipl. ACPV
Director of Clinical Research, Zoetis

With the advantage of using the latest molecular techniques, Zoetis identified a unique genome insertion site for the optimal recombinant to express the ND protein to deliver a highly effective immune response.

Download Study

Strengthen Your Respiratory Protection

With Poulvac^® Procerta^™ HVT‑ND, Zoetis offers the industry’s most comprehensive respiratory vaccine portfolio.

Broadest IB Line

Our extensive infectious bronchitis (IB) vaccine line provides greater flexibility to customize respiratory programs based on local challenges, with antigenically diverse vaccines that include Ark, Mass, Ark + Mass, GA98 and GA08.

VISIT respiratory microsite >

Flexible ND Options

The Poulvac^® vaccine portfolio offers a vector HVT‑ND and Poulvac Aero^®, a live vaccine protecting against Newcastle disease and IB, based on your respiratory needs.

IBD Compatibility

Poulvac^® Procerta^™ HVT‑ND can be administered with live and immune‑complex bursal disease vaccines, such as Poulvac^® Bursaplex^®, when hatcheries rotate from HVT‑IBD vaccines.